Counterweight Ventures’s BioCryst Pharmaceuticals BCRX Stock Holding History

Counterweight Ventures’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$621K	Sell	62,050 -33,334	-35%	-$301K	0.31%	58
2026 Q1	$908K	Hold	95,384	–	–	0.51%	54
2025 Q4	$744K	Buy	95,384 +2,000	+2%	+$14.5K	0.42%	52
2025 Q3	$709K	Hold	93,384	–	–	0.41%	52
2025 Q2	$837K	Hold	93,384	–	–	0.55%	46
2025 Q1	$700K	Hold	93,384	–	–	0.5%	46
2024 Q4	$702K	Hold	93,384	–	–	0.5%	46
2024 Q3	$710K	Buy	93,384 +79,884	+592%	+$607K	0.5%	47
2024 Q2	$83.4K	Hold	13,500	–	–	0.06%	63
2024 Q1	$68.6K	Hold	13,500	–	–	0.06%	64
2023 Q4	$80.9K	Buy	+13,500	New	+$78.2K	0.07%	61

Other funds holding BCRX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

OAM

OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PFC

Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

QFW

QTR Family Wealth Lake Mary, Florida $287M AUM 40.55% 1-Year Est. Return

Counterweight Ventures's BCRX Position: Q2 2026 in Review

Counterweight Ventures reduced its BioCryst Pharmaceuticals (BCRX) stake by 35% in Q2 2026, selling an estimated $301K and leaving 62,050 shares worth $621K. The position accounts for 0.31% of the portfolio, ranked #58.

Counterweight Ventures first reported a position in BCRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $908K in Q1 2026. 68 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Counterweight Ventures held 62,050 shares of BioCryst Pharmaceuticals worth $621K as of Q2 2026.
Counterweight Ventures sold 33,334 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $301K.
BioCryst Pharmaceuticals made up 0.31% of Counterweight Ventures's portfolio in Q2 2026, its #58 holding.
Counterweight Ventures first reported a position in BioCryst Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Counterweight Ventures's BioCryst Pharmaceuticals position peaked at $908K in Q1 2026.
68 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Counterweight Ventures's 13F filing for Q2 2026, filed 23 Jul 2026.